Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

Why don’t we support Chairman Waxman or Senator Schumer’s legislation?

April 26, 2017Chairman don’t legislation schumer Senator support waxman

0

Posted

Why don’t we support Chairman Waxman or Senator Schumer’s legislation?

1 Answer

0

Posted

Chairman Waxman’s and Senator Schumer’s (D-NY) legislation (H.R.1427 / S.726) only provide at most 5 years of data protection for biologics, and a less fair way of addressing patent protection. This means manufacturers of biologics would face considerably less certainty over the timing of follow-on biologic market entry. This could dramatically hinder future innovation as it could greatly impact research and development investment needed to generate new biologic medicines and new uses for biologics to treat some of the most challenging diseases facing patients today.